Prominent publications by Paul Haluska

KOL Index score: 42 . I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a monoclonal antibody designed to bind and inhibit function of the type I insulin-like growth factor receptor (IGF-1R). Ganitumab was tested in combination with metformin and paclitaxel (PGM) followed by AC compared to standard-of-care alone. While ...

Key People For Purkinje Cell

Top KOLs in the world
#1
Constantino Sotelo
purkinje cells mutant mice cerebellar cortex
#2
Rodolfo R Llinás
purkinje cells squid giant synapse transmitter release
#3
Joseph Altman
cerebellar cortex purkinje cells molecular layer
#4
Francis Crépel
purkinje cells climbing fibres multiple innervation
#5
Masanobu Masanobu
purkinje cells synapse elimination synaptic transmission
#6
Chris Innocentius De Zeeuw
purkinje cells cerebellar nuclei inferior olive

Paul Haluska:Expert Impact

Concepts for whichPaul Haluskahas direct influence:Purkinje cell,  Presenting symptom,  Standard neoadjuvant therapy,  Combination metformin,  Pca1igg autoantibodies,  Ganitumab ganitumab response,  Patient pain.

Paul Haluska:KOL impact

Concepts related to the work of other authors for whichfor which Paul Haluska has influence:Autoimmune pain,  Rad51 gene expression,  Peripheral neuropathies,  Aggressive biology,  Cancer drug resistance,  Rppa proteomic analysis,  Protein array.


 

Tools

Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


Mayo Clinic Rochester c/o Merck Corporation, 126 E. Lincoln Ave Rahway, New Jersey, 07065 USA | Mayo Clinic Department of Medical Oncology Rochester Minnesota USA

download
FREE Custom List